Analyzing TransEnterix and Nanovibronix Medical Companies

Which small-cap medical device firm is the superior business?

Published on Feb. 16, 2026

Got story updates? Submit your updates here. ›

TransEnterix (OTCMKTS:TRXDW) and Nanovibronix (NASDAQ:FEED) are both small-cap medical companies, but a comparison of the two reveals key differences in institutional ownership, insider holdings, profitability, and valuation.

Why it matters

Investors looking to gain exposure to the medical device industry may be weighing the relative merits of these two small-cap firms, which have differing business models, financial performance, and market positioning.

The details

TransEnterix is focused on robotic surgical systems, while Nanovibronix develops medical products using acoustic wave technology. The analysis shows Nanovibronix has stronger institutional ownership, lower insider holdings, and more favorable profitability metrics compared to TransEnterix. Additionally, Nanovibronix trades at a lower price-to-earnings ratio, indicating it may be the more affordable of the two stocks.

  • The analysis is based on data as of February 16, 2026.

The players

TransEnterix, Inc.

A medical device company that engages in the research, development, and sale of robotic surgical systems, primarily the Senhance System in Europe.

Nanovibronix Inc.

A medical device company focused on creating products utilizing its proprietary low-intensity, surface acoustic wave technology, including the UroShield and NG-Shield devices.

Got photos? Submit your photos here. ›

The takeaway

Investors evaluating small-cap medical device firms should carefully consider factors like institutional ownership, profitability, and valuation when assessing the relative merits of companies like TransEnterix and Nanovibronix.